Product Name: Human Integrin a4b7 (ITGA4 & ITGB7) Antibody (Etrolizumab, Research Use)
Catalog Number: NBR-0618
Target Name: Integrin a4b7 (ITGA4 & ITGB7)
Trade Name: Etrolizumab
Antibody Drug Description: Etrolizumab (rhuMAb Beta7) is the first dual-action anti-integrin antibody in Phase III trials designed to selectively control disease in the gut of patients with two major forms of inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn’s disease (CD). It is a humanized monoclonal antibody against the β7 subunit of integrins α4β7 and αEβ7. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name:  ITGA4 & ITGB7
Synonyms: CD49D
Target Description: Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. Integrin alpha-4/beta-7 (Peyer patches-specific homing receptor LPAM-1) is an adhesion molecule that mediates lymphocyte migration and homing to gut-associated lymphoid tissue (GALT). Integrin alpha-4/beta-7 interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract.
Ensembl:  ENSG00000115232; ENSG00000139626
Uniprot:  P13612; P26010